Viewing Study NCT04699357


Ignite Creation Date: 2025-12-24 @ 6:51 PM
Ignite Modification Date: 2025-12-29 @ 4:05 PM
Study NCT ID: NCT04699357
Status: UNKNOWN
Last Update Posted: 2022-01-26
First Post: 2021-01-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial
Sponsor: Shanghai Eye Disease Prevention and Treatment Center
Organization:

Study Overview

Official Title: Shanghai Eye Disease Prevention and Treatment Center
Status: UNKNOWN
Status Verified Date: 2021-01
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Objective: to evaluate the efficacy of different concentrations of atropine eye drops in controlling the progression (diopter, axial length) of high myopia in young children, and to compare the compliance, adverse reaction and regression rate of different concentrations of atropine eye drops in myopia control.

Intervention: Group 1 (0.01% atropine group), Group 2 (0.04% atropine group), Group 3 (0.1% atropine group). During the 2-year intervention period after entering the group, each concentration of atropine eye drops were given every night at a fixed time before going to bed, one drop each time, implemented by parents (supervision), and the wechat small program was completed.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: